Comparing Halo Laser and BBL: Key Differences Treatment Depth Halo Laser penetrates deeper into the skin, making it best for significant texture issues, scarring, and deeper wrinkles
Optimal cycle frequency Most protocols recommend one to two complete cycles per year for general anti-aging applications
Poster Session I - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.01 - PATHOPHYSIOLOGY OF STROKE / TRANSLATIONAL MEDICINE P472 - ESOC25-1380 ASSOCIATION BETWEEN COGNITIVE FUNCTION AND CEREBROVASCULAR RESERVE: IMPACT OF HBA1C Mami Ishikawa 1,2 , Masashi Ikota 1 , Taku Uchiyama 1 , Heiji Naritaka 2 , Gen Kusaka 1 1 Saitama Medical Center, Jichi Medical University, Saitama, Japan, 2 Edogawa Hospital, Tokyo, Japan Background and Aims: Cognitive impairment has been reported in patients with steno-occlusive disease of a main cerebral artery without causative lesions on magnetic resonance imaging
Transition metal ions at the crossroads of mucosal immunity and microbial pathogenesis
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
